Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies?: a review from the chronic malignancies working party of the EBMT
Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 May 2020
|
| In: |
Biology of blood and marrow transplantation
Year: 2020, Jahrgang: 26, Heft: 9, Pages: 1559-1566 |
| ISSN: | 1523-6536 |
| DOI: | 10.1016/j.bbmt.2020.04.016 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.bbmt.2020.04.016 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S1083879120302226 
|
| Verfasserangaben: | Laurent Garderet, Curly Morris, Meral Beksac, Gösta Gahrton, Stefan Schönland, Ibrahim Yakoub-Agha, Patrick J. Hayden |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1744988358 | ||
| 003 | DE-627 | ||
| 005 | 20230426074226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210119s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbmt.2020.04.016 |2 doi | |
| 035 | |a (DE-627)1744988358 | ||
| 035 | |a (DE-599)KXP1744988358 | ||
| 035 | |a (OCoLC)1341388997 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Garderet, Laurent |d 1964- |e VerfasserIn |0 (DE-588)1161564748 |0 (DE-627)1024850803 |0 (DE-576)506738337 |4 aut | |
| 245 | 1 | 0 | |a Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? |b a review from the chronic malignancies working party of the EBMT |c Laurent Garderet, Curly Morris, Meral Beksac, Gösta Gahrton, Stefan Schönland, Ibrahim Yakoub-Agha, Patrick J. Hayden |
| 264 | 1 | |c 15 May 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.10.2021 | ||
| 520 | |a Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric antigen receptor T cells are challenging the traditional role of ASCT. Which patients benefit from ASCT? Can its use be delayed until first relapse? The field is moving rapidly as novel agents lead to new patient care strategies. The place of ASCT in this changing landscape will be reviewed and reassessed. | ||
| 650 | 4 | |a Autologous stem cell transplantation | |
| 650 | 4 | |a CAR T cells | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Myeloma | |
| 700 | 1 | |a Schönland, Stefan |d 1969- |e VerfasserIn |0 (DE-588)122405226 |0 (DE-627)705896137 |0 (DE-576)293255792 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biology of blood and marrow transplantation |d [Erscheinungsort nicht ermittelbar] : Elsevier Health Sciences, 1998 |g 26(2020), 9, Seite 1559-1566 |h Online-Ressource |w (DE-627)334374782 |w (DE-600)2057605-5 |w (DE-576)118352229 |x 1523-6536 |7 nnas |a Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? a review from the chronic malignancies working party of the EBMT |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:9 |g pages:1559-1566 |g extent:8 |a Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? a review from the chronic malignancies working party of the EBMT |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bbmt.2020.04.016 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1083879120302226 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210119 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 122405226 |a Schönland, Stefan |m 122405226:Schönland, Stefan |d 50000 |d 910000 |d 910100 |e 50000PS122405226 |e 910000PS122405226 |e 910100PS122405226 |k 0/50000/ |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1744988358 |e 3839350328 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Garderet, Laurent","family":"Garderet","given":"Laurent","role":"aut"},{"role":"aut","given":"Stefan","family":"Schönland","display":"Schönland, Stefan"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"15 May 2020"}],"note":["Gesehen am 22.10.2021"],"title":[{"title_sort":"Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies?","subtitle":"a review from the chronic malignancies working party of the EBMT","title":"Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies?"}],"id":{"doi":["10.1016/j.bbmt.2020.04.016"],"eki":["1744988358"]},"name":{"displayForm":["Laurent Garderet, Curly Morris, Meral Beksac, Gösta Gahrton, Stefan Schönland, Ibrahim Yakoub-Agha, Patrick J. Hayden"]},"physDesc":[{"extent":"8 S."}],"recId":"1744988358","relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? a review from the chronic malignancies working party of the EBMTBiology of blood and marrow transplantation","title":[{"title":"Biology of blood and marrow transplantation","subtitle":"BBMT ; the official journal of the American Society for Blood and Marrow Transplantation","title_sort":"Biology of blood and marrow transplantation"}],"note":["Gesehen am 16.03.2021"],"pubHistory":["Volume 4, issue 1 (June 1998)-Volume 26, issue 12 (December 2020)"],"origin":[{"publisherPlace":"[Erscheinungsort nicht ermittelbar] ; Charlottesville, Va.","publisher":"Elsevier Health Sciences ; Carden Jennings","dateIssuedDisp":"[1998-2020]"}],"id":{"eki":["334374782"],"issn":["1523-6536"],"zdb":["2057605-5"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"334374782","titleAlt":[{"title":"BBMT"}],"part":{"text":"26(2020), 9, Seite 1559-1566","issue":"9","year":"2020","pages":"1559-1566","extent":"8","volume":"26"},"language":["eng"]}]} | ||
| SRT | |a GARDERETLAAREAUTOLOG1520 | ||